Changes

m
Line 474: Line 474:  
|
 
|
 
|-
 
|-
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg r
+
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg
Conboy (Monash Health)
+
Corboy (Monash Health)
 
|
 
|
 
|
 
|
Line 491: Line 491:  
|Add WHO reference
 
|Add WHO reference
 
|-
 
|-
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Conboy (Monash Health)
+
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Corboy (Monash Health)
 
|
 
|
 
|
 
|
Line 709: Line 709:  
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
 
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
 
|Disease
 
|Disease
|Kay Weng Choy + Greg Conboy (Monash Health)
+
|Kay Weng Choy + Greg Corboy (Monash Health)
 
|
 
|
 
|
 
|
Line 1,307: Line 1,307:  
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 
|
 
|
|
+
|Requested to update 14022022
 
|-
 
|-
 
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
 
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
Line 1,395: Line 1,395:  
| ||GC
 
| ||GC
 
|
 
|
|
+
|Contacted Jan 2022 no reply, followed up with Fabiola Feb 2022
 
|-
 
|-
 
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
 
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera